Bird Rock Bio, Inc.

By 2040, over half a billion people could be taking GLP-1 agonists or other weight loss medicines, according to McKinsey. A market that barely existed prior to 2021 could be worth over $100bn by 2030

Radionetics Oncology , a three-year-old start-up that has raised $82.5m to date, landed a sweet deal with Eli Lilly and Company , with the big pharma paying $140m up front for an exclusive right to b

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Leo To Pay $14m For Timber, Plus Milest

Janssen Biotech Inc. affiliate Cilag GMBH International and the Belgian biotech argenx SE have inked a global collaboration and license deal for cusatuzumab, argenx’s anti-CD70 antibody in blood